Patents by Inventor Joseph J. Buggy

Joseph J. Buggy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220175785
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: February 18, 2022
    Publication date: June 9, 2022
    Inventors: Joseph J. Buggy, Gwen Fyfe, Laurence Elias, David J. Loury
  • Publication number: 20210361657
    Abstract: Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.
    Type: Application
    Filed: December 16, 2020
    Publication date: November 25, 2021
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Publication number: 20210169885
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: July 10, 2020
    Publication date: June 10, 2021
    Inventors: Joseph J. Buggy, Gwen Fyfe, Lee Honigberg, David J. Loury
  • Publication number: 20210145835
    Abstract: Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.
    Type: Application
    Filed: June 29, 2020
    Publication date: May 20, 2021
    Inventors: Jun Chen, Joseph J. Buggy, Laurence Elias
  • Patent number: 10954567
    Abstract: Described herein are mutations that confer resistance to treatment with a BTK inhibitor. Described herein are modified BTK polypeptides that exhibit decreased inhibition (i.e. are resistant) to a covalent and/or irreversible BTK inhibitor. Also described herein modifications of PLCy2 and CARD 11 polypeptides that confer resistance to treatment with a BTK inhibitor. Described herein are diagnostic methods for detecting the modified polypeptides and nucleic acids encoding the modified polypeptides and applications of the methods thereof. Described herein are compositions, combinations, and kits containing the modified polypeptides and methods of using the modified polypeptides. Also described herein are methods of using modified BTK polypeptides as screening agents for the identification and design of second-generation BTK inhibitors.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: March 23, 2021
    Assignees: Pharmacyclics LLC, Cornell University
    Inventors: Betty Chang, Joseph J. Buggy, Susanne M. Steggerda
  • Publication number: 20200289515
    Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
    Type: Application
    Filed: March 21, 2019
    Publication date: September 17, 2020
    Inventors: Lee Honigberg, Erik J. Verner, Joseph J. Buggy, David J. Loury, Wei Chen
  • Publication number: 20200276199
    Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
    Type: Application
    Filed: February 28, 2019
    Publication date: September 3, 2020
    Inventors: Joseph J. Buggy, Laurence Elias
  • Patent number: 10751342
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: August 25, 2020
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Gwen Fyfe, Lee Honigberg, David J. Loury
  • Publication number: 20200246259
    Abstract: Disclosed herein are methods for treating an individual diagnosed with ABC-DLBCL. The methods include administering to the individual an inhibitor of Bruton's tyrosine kinase (Btk).
    Type: Application
    Filed: April 3, 2020
    Publication date: August 6, 2020
    Inventors: Joseph J. Buggy, Louis M. Staudt, Wyndham H. Wilson
  • Publication number: 20200163968
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: January 21, 2020
    Publication date: May 28, 2020
    Inventors: Joseph J. Buggy, Gwen Fyfe, Lee Honigberg, David J. Loury
  • Patent number: 10653696
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: May 19, 2020
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Gwen Fyfe, Lee Honigberg, David J. Loury
  • Publication number: 20200147084
    Abstract: Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.
    Type: Application
    Filed: May 21, 2019
    Publication date: May 14, 2020
    Inventors: Joseph J. Buggy, Tarak D. Mody, John C. Byrd, Betty Y. Chang, Jason A. Dubovsky, Natarajan Muthusamy, Amy J. Johnson
  • Publication number: 20200055859
    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
    Type: Application
    Filed: March 22, 2019
    Publication date: February 20, 2020
    Inventors: Joseph J. Buggy, Wei Chen, Lee Honigberg, David J. Loury, Zhengying Pan, Erik J. Verner
  • Publication number: 20190358234
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: August 8, 2019
    Publication date: November 28, 2019
    Inventors: Joseph J. Buggy, Gwen Fyfe, Lee Honigberg, David J. Loury
  • Publication number: 20190184196
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Application
    Filed: October 18, 2018
    Publication date: June 20, 2019
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian
  • Publication number: 20190167687
    Abstract: Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.
    Type: Application
    Filed: July 6, 2018
    Publication date: June 6, 2019
    Inventors: Jun Chen, Joseph J. Buggy, Laurence Elias
  • Publication number: 20180311153
    Abstract: Disclosed herein are methods for treating an individual diagnosed with ABC-DLBCL. The methods include administering to the individual an inhibitor of Bruton's tyrosine kinase (Btk).
    Type: Application
    Filed: December 1, 2017
    Publication date: November 1, 2018
    Inventors: Joseph J. Buggy, Louis M. Staudt, Wyndham H. Wilson
  • Patent number: 10105552
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 23, 2018
    Assignee: Pharmacyclics LLC
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian
  • Publication number: 20180280395
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: May 2, 2018
    Publication date: October 4, 2018
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Publication number: 20180256581
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: April 27, 2018
    Publication date: September 13, 2018
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody